PMID- 37272809
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20230809
IS  - 1556-9535 (Electronic)
IS  - 1556-9527 (Linking)
VI  - 42
IP  - 3
DP  - 2023 Sep
TI  - Tamoxifen related chorioretinal structural changes.
PG  - 109-117
LID - 10.1080/15569527.2023.2220388 [doi]
AB  - PURPOSE: To evaluate the vascular structure of the choroid and each retinal layer 
      in patients with breast cancer on tamoxifen therapy and compare them with healthy 
      subjects. MATERIALS AND METHODS: 124 eyes of 62 patients with breast cancer who 
      were on tamoxifen therapy (group 1) and 80 eyes of 40 healthy controls (group 2) 
      were included in this prospective cohort study. The structure of the choroid was 
      evaluated using enhanced depth imaging spectral-domain optical coherence 
      tomography (EDI-OCT) and choroidal binarisation. Spectral-domain OCT (SD-OCT) was 
      performed to analyse the peripapillary nerve fibre layer thickness (pRNFL) and 
      each retinal layer thickness. A subgroup analysis was performed based on 
      chemotherapy history in Group 1. All parameters were compared between Group 1 and 
      the healthy controls and between the subgroups of Group 1. RESULTS: The subfoveal 
      choroidal thickness and temporal and nasal directions were increased in Group 1 
      when compared with Group 2 (p < 0.05, each comparison). Choroidal vascularity 
      index was significantly decreased in Group 1 compared with Group 2 (63.15 +/- 3.11% 
      and 65.37 +/- 4.63%, p < 0.001). There were no significant differences in each 
      retinal layer, pRNFL thickness, and choroid structural parameters between the 
      subgroups of Group 1. CONCLUSIONS: Increased choroidal thickness may be the 
      initial finding of subclinical tamoxifen-induced retinopathy. Patients with 
      breast cancer undergoing tamoxifen therapy may be screened prior to tamoxifen 
      therapy and followed during treatment by SD-OCT.
FAU - Erbahceci Timur, Inci Elif
AU  - Erbahceci Timur IE
AD  - Ministry of Health Ankara City Hospital, Ophthalmology Clinic, Ankara, Turkey.
FAU - Acikgoz, Vehbi
AU  - Acikgoz V
AD  - Ministry of Health Ankara City Hospital, Ophthalmology Clinic, Ankara, Turkey.
FAU - Ugurlu, Nagihan
AU  - Ugurlu N
AD  - Ministry of Health Ankara City Hospital, Ophthalmology Clinic, Ankara, Turkey.
FAU - Yalcin, Bulent
AU  - Yalcin B
AD  - Ministry of Health Ankara City Hospital, Oncology Clinic, Ankara, Turkey.
FAU - Sendur, Mehmet Ali Nahit
AU  - Sendur MAN
AD  - Ministry of Health Ankara City Hospital, Oncology Clinic, Ankara, Turkey.
FAU - Hizal, Mutlu
AU  - Hizal M
AD  - Ministry of Health Ankara City Hospital, Oncology Clinic, Ankara, Turkey.
FAU - Kara, Halil
AU  - Kara H
AD  - Department of Pharmocology, Yildirim Beyazit University, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230615
PL  - England
TA  - Cutan Ocul Toxicol
JT  - Cutaneous and ocular toxicology
JID - 101266892
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - Humans
MH  - Female
MH  - Tamoxifen/adverse effects
MH  - Prospective Studies
MH  - Retina/diagnostic imaging
MH  - Choroid/diagnostic imaging/blood supply
MH  - Tomography, Optical Coherence/methods
MH  - *Retinal Diseases
MH  - *Breast Neoplasms/drug therapy
OTO - NOTNLM
OT  - Choroidal thickness
OT  - choroidal vascularity index
OT  - image binarisation
OT  - spectral-domain optical coherence tomography
OT  - tamoxifen-induced chorioretinopathy
EDAT- 2023/06/05 13:05
MHDA- 2023/08/09 06:43
CRDT- 2023/06/05 10:04
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/06/05 13:05 [pubmed]
PHST- 2023/06/05 10:04 [entrez]
AID - 10.1080/15569527.2023.2220388 [doi]
PST - ppublish
SO  - Cutan Ocul Toxicol. 2023 Sep;42(3):109-117. doi: 10.1080/15569527.2023.2220388. 
      Epub 2023 Jun 15.